Abstract:BackgroundTislelizumab, an anti-programmed cell death protein-1 monoclonal antibody, demonstrated clinical activity and was well tolerated in patients with previously treated advanced HCC in the open-label, multicenter, Phase 2 RATIONALE-208 study (NCT03419897). We report exploratory analysis of the association of gene expression profiles (GEPs) with response to tislelizumab in patients with previously treated advanced HCC.MethodsEligible patients who had received ≥1 prior line of systemic therapy for advanced HCC received tislelizumab (200 mg) intravenously once every 3 weeks and tumor response was evaluated per RECIST v.1.1. Baseline tumor sampling was optional and GEP analysis was performed using HTG EdgeSeq Precision Immuno-Oncology panel in 138 tumor samples (fresh tumor, n=6; archival tumor, n=132). Signature scores were calculated using Gene Set Variation Analysis package with publicly available gene signatures (GS). GS or genes differentially expressed between responders and non-responders (NRs) were determined using Wilcoxon rank-sum test and modified t-test with limma. Distributions of overall survival (OS) and progression-free survival (PFS) for GS subgroups (high vs low) were estimated by Kaplan-Meier method. Hierarchical clustering of NRs was achieved using 1-Pearson’s correlation and average linkage. All statistical analysis results are post-hoc exploratory and thereby p values are descriptive.Results249 patients were enrolled and received ≥1 dose of tislelizumab; 138 patients had evaluable GEP data, of which 132 patients had evaluable GEP and tumor response data. GEP analysis demonstrated that CD4 T cell, CD8 T cell, cytotoxic T lymphocyte and major histocompatibility complex class I signatures were enriched in responders, and cancer-associated fibroblasts, angiogenesis and hypoxia signatures were enriched in NRs (figure 1). CD8B_PDCD1_9, a novel GS identified, comprises 9 genes highly expressed in responders: CD8B, CXCL13, KLRD1, NKG7, HLA-A, HLA-G, LAG3, PDCD1 and KREMEN1. Higher objective response rate (ORR; p<0.0001, by Fisher’s exact test) and longer PFS (p=0.005, by log rank test) were observed in patients with high vs low CD8B_PDCD1_9 score (ORR: 26% vs 3%; median PFS: 2.8 months vs 1.8 months). To explore the heterogeneity of molecular features in NRs, NRs were clustered into 3 subgroups using a series of tumor-immune GS. OS and PFS for the 3 NR subgroups with distinct GS are summarized in table 1.Abstact 360 Figure 1Correlation between GS and ORR in patients with previously treated advanced HCC treated with tislelizumab monotherapyAbstact 360 Table 1OS and PFS of NR subgroupsCl, confidence interval; NE, not evaluable; GS, gene signature; NR, non-responder; OS, overall survival; PFS, progression-free survivalConclusionsThis exploratory analysis identified distinct GS associated with tumor response and resistance to tislelizumab monotherapy in patients with previously treated advanced HCC and increases our understanding of the tumor microenvironment. Further GEP analyses will be undertaken in an on-going Phase 3 study (NCT03412773).AcknowledgementsThis study is sponsored by BeiGene Ltd. Medical writing support for the development of this abstract, under direction of the authors, was provided by Claire White, PhD, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene Ltd.Trial RegistrationNCT03419897Ethics ApprovalThis study was conducted according to the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, the principles of informed consent and the requirements of the public registration of clinical trials. Written informed consent was obtained from each patient prior to screening. The protocol was approved by the institutional ethics committee and was monitored by a safety monitoring committee.

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma

360 Tumor-immune Signatures Associated with Response or Resistance to Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)

372 Association of Tumor Mutation Burden (TMB) and Genomic Alterations (GA) with Clinical Outcomes in Chinese Patients with Advanced Solid Tumors Treated with Tislelizumab

Tislelizumab in Combination with Chemotherapy in Chinese Patients with Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Results from One Cohort of an Ongoing Phase 2 Study.

78 T-Cell, MHC I, and Tumor Intrinsic Gene Signatures Predict Clinical Benefit and Resistance to Tislelizumab Monotherapy in Pretreated PD-L1+ Urothelial Carcinoma

Immune- and Tumor-Intrinsic Gene Expression Profiles of Response or Resistance to Tislelizumab As Monotherapy or in Combination with Chemotherapy in Non-Small Cell Lung Cancer (NSCLC).

Tumor Mutational Burden Identifies Chemorefractory Gastric Cancer with Overall Survival Advantage after Receiving Toripalimab, a PD-1 Antibody.

Abstract 6400: Tislelizumab combined with XELOX as a neoadjuvant therapy for locally advanced gastric and gastroesophageal junction adenocarcinomas: A prospective, phase II trial

Abstract CT044: Genomic Correlates of Clinical Benefits from Atezolizumab Combined with Bevacizumab Vs. Atezolizumab Alone in Patients with Advanced Hepatocellular Carcinoma (HCC)

Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma.

Abstract 5129: Clinical implication of plasma ctDNA features in HER2-positive gastric cancer treated with combinations of trastuzumab & anti-PD-1 agents

77 Association Between Programmed Death-Ligand 1 (PD-L1) Expression and Gene Signatures of Response or Resistance to Tislelizumab Monotherapy in Hepatocellular Carcinoma (HCC)

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Abstract 620: Associations of Genomic Alteration, Tumor Mutational Burden with PD-L1 Expression and Response to Immune Checkpoint Inhibitors in Chinese Lung Patients

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study

Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma

The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1

Tumor microenvironment evaluation to predict anti–PD-1 response of advanced gastric cancer: Results from a multicenter prospective clinical trial.

Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients

Abstract CT053: Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)